Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy
- 30 September 2024
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (12) , 1763-1772
Abstract
Systemic corticosteroid therapy is a well-established first-line treatment for grades II–IV acute graft-versus-host disease (aGVHD). Recently, several developments have occurred, including the introduction of transplantation from human leukocyte antigen (HLA) haploidentical donors using post-transplant cyclophosphamide (PTCY-Haplo), and improvements in prognosis after cord blood transplantation (CBT) in Japan. This study aimed to analyze the association between donor sources and outcomes in patients with aGVHD. Our study included 2732 patients who developed grades II–IV aGVHD, and were treated with systemic corticosteroids. We compared HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD), PTCY-Haplo, and CBT. We set endpoint as response rate, 1-year cumulative incidence of non-relapse mortality (NRM), and overall survival (OS). The adjusted odds ratios for a complete response (CR) were 0.99 (95% confidence interval [CI]: 0.74–1.31, P = 0.925) for MUD, 2.08 (95% CI: 1.35–3.25, P = 0.001) for PTCY-Haplo, and 1.08 (95% CI: 0.83–1.41, P = 0.550) for CBT compared with MRD. A significant increase in response rates for PTCY were only found in a single-organ involvement. No significant association was observed between the donor source and NRM or OS. In conclusion, PTCY-Haplo is associated with a high response rate in patients with a single-organ aGVHD; however, MUD and CBT were not associated with treatment response.Keywords
This publication has 24 references indexed in Scilit:
- Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017American Journal of Hematology, 2019
- Validation of Minnesota acute graft- versus -host disease Risk ScoreHaematologica, 2019
- Steroid treatment of acute graft- versus -host disease grade I: a randomized trialHaematologica, 2017
- Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translationBlood, 2016
- Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trialHaematologica, 2015
- Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomesBlood, 2009
- Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factorsBlood, 2009
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- A retrospective analysis of therapy for acute graft-versus-host disease: initial treatmentBlood, 1990
- Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcomeBlood, 1990